Hyriem Tablet 10/5 mg (Empagliflozin, Linagliptin)
Empagliflozin Micronized 10mg · Linagliptin Micronized 5mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
MFDS item code 202402465 · Approved 2024.10.21
Improvement of blood glucose control in patients with type 2 diabetes
This medication is used to improve blood sugar control in patients with type 2 diabetes. It is particularly effective as an adjunct to dietary and exercise therapy when combined use of empagliflozin and linagliptin is appropriate. It helps manage blood sugar levels stably to assist in diabetes treatment.
The recommended starting dose of this medicine is empagliflozin 10 mg/linagliptin 5 mg once daily. If additional glycemic control is needed and empagliflozin 10 mg/linagliptin 5 mg is tolerated, the dose of this medicine may be increased to 25/5 mg once daily. Patients switching to this medicine from concomitant therapy with empagliflozin and linagliptin should receive their existing doses. This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. However, if it is within 12 hours of your next dose, skip the missed dose and take your next dose at the usual time. Do not take a double dose in one day. Patients with renal impairment: This medicine is not recommended for improving glycemic control in patients with an estimated glomerular filtration rate (eGFR) below 45 ml/min/1.73m2. No dose adjustment is required in patients with an estimated glomerular filtration rate of 45 ml/min/1.73m2 or higher. Patients with hepatic impairment: No dose adjustment is required in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. Older adults: No dose adjustment based on age is required. In patients aged 75 years and older, renal function and the risk of volume depletion should be considered.
This medication contains empagliflozin and linagliptin, and is used for diabetes treatment. First, this medication should not be used in patients who are allergic to empagliflozin, linagliptin, or other components of this medication, in patients with type 1 diabetes, diabetic ketoacidosis, or patients undergoing dialysis. Patients with impaired kidney function may experience reduced effectiveness of this medication, so regular kidney function tests should be conducted before and during treatment, and caution is needed if taking other medications that may affect kidney function. Careful use is required for patients with mild to moderate heart failure (New York Heart Association Functional Classification I-II), while it is not recommended for patients with severe heart failure (Classification III-IV). This medication carries a risk of pancreatitis; if severe abdominal pain persists, consult a doctor immediately and consider discontinuing use. Additionally, there may be a risk of blistering similar to bullous pemphigoid; notify medical personnel immediately if any skin abnormalities occur. The most common side effect is urinary tract infection; in addition, hypoglycemia, thirst, cough, constipation, itching, rash, and increased urination have also been reported. Particularly when taken with medications that pose a risk of hypoglycemia, such as insulin or sulfonylureas, the risk of hypoglycemia increases, so blood sugar levels should be monitored closely. This medication can cause hypotension or dehydration due to fluid loss, so special caution is required for elderly patients or those with low blood pressure, and treatment may be temporarily suspended in cases of dehydration. Moreover, this medication may increase the risk of genital fungal infections, and appropriate treatment may be necessary if relevant symptoms develop. It is advisable not to use this medication during pregnancy unless under special circumstances, and discontinuation of breastfeeding is recommended if nursing. The safety and efficacy in children under 18 years have not been established, so it should not be used in this age group. In case of overdose, appropriate medical treatment should be sought immediately, and this medication should be kept out of the reach of children. During treatment, caution should be exercised when driving or operating machinery due to the risk of hypoglycemia, especially when taken with other hypoglycemia-inducing medications. Finally, diabetic patients should pay attention to foot care as usual, and if they experience pain or swelling around the perineum while taking this medication, they should inform medical personnel immediately and seek treatment.
Not everyone experiences these, and they can vary from person to person.
This medication should be kept in a tightly sealed container to prevent exposure to air or moisture. The recommended storage temperature is room temperature between 1 to 30 degrees Celsius. This helps maintain the effectiveness of the medication and ensures safe use.
Flat on both sides and a thin triangular film-coated tablet with sharp edges that is pale yellow
Bottle - 30 tablets/bottle, PTP - 30 tablets/box [10 tablets/PTP x 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Empagliflozin Micronized 10mg · Linagliptin Micronized 5mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Empagliflozin Micronized 25mg · Linagliptin Micronized 5mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.